Cargando…
Complement C3 is a novel modulator of the anti-factor VIII immune response
Development of neutralizing antibodies against therapeutic Factor VIII (FVIII) is the most serious complication of the treatment of hemophilia A. There is growing evidence to show the multifactorial origin of the anti-FVIII immune response, combining both genetic and environmental factors. While a r...
Autores principales: | Rayes, Julie, Ing, Mathieu, Delignat, Sandrine, Peyron, Ivan, Gilardin, Laurent, Vogel, Carl-Wilhelm, Fritzinger, David C., Frémeaux-Bacchi, Véronique, Kaveri, Srinivas V., Roumenina, Lubka T., Lacroix-Desmazes, Sébastien |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792280/ https://www.ncbi.nlm.nih.gov/pubmed/29146705 http://dx.doi.org/10.3324/haematol.2017.165720 |
Ejemplares similares
-
Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A
por: Delignat, Sandrine, et al.
Publicado: (2019) -
Complement System Part I – Molecular Mechanisms of Activation and Regulation
por: Merle, Nicolas S., et al.
Publicado: (2015) -
Complement System Part II: Role in Immunity
por: Merle, Nicolas S., et al.
Publicado: (2015) -
Ex Vivo Test for Measuring Complement Attack on Endothelial Cells: From Research to Bedside
por: Meuleman, Marie-Sophie, et al.
Publicado: (2022) -
Relevance of the Materno-Fetal Interface for the Induction of Antigen-Specific Immune Tolerance
por: Mimoun, Angelina, et al.
Publicado: (2020)